Pyxis Oncology is trading 5.14% higher at $2.25 on October 5, 2026, with no company-specific announcement or report identified to explain the intraday rise.

  • The latest company news is the October 2 closing of a public offering that brought in approximately $110 million upfront, with potential additional proceeds tied to future clinical data milestones.
  • Major indexes are positive, but available evidence does not establish a market-driven cause.